BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35701827)

  • 1. Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy.
    Adrian G; Carlsson H; Kjellén E; Sjövall J; Zackrisson B; Nilsson P; Gebre-Medhin M
    Radiat Oncol; 2022 Jun; 17(1):107. PubMed ID: 35701827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors.
    Adrian G; Gebre-Medhin M; Nilsson P
    Acta Oncol; 2023 Nov; 62(11):1375-1383. PubMed ID: 37682690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study.
    Kristensen MH; Sørensen MK; Tramm T; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Lilja-Fischer JK; Holm AIS; Samsøe E; Hansen CR; Zukauskaite R; Overgaard J; Eriksen JG
    Radiother Oncol; 2024 Apr; 193():110149. PubMed ID: 38341096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
    Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P;
    Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
    Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
    Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylhä C; Marklund L; Näsman A; Sivars L; Dalianis T
    Oral Oncol; 2024 Apr; 151():106749. PubMed ID: 38461771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
    Chung CH; Zhang Q; Kong CS; Harris J; Fertig EJ; Harari PM; Wang D; Redmond KP; Shenouda G; Trotti A; Raben D; Gillison ML; Jordan RC; Le QT
    J Clin Oncol; 2014 Dec; 32(35):3930-8. PubMed ID: 25267748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?
    Fischer CA; Zlobec I; Green E; Probst S; Storck C; Lugli A; Tornillo L; Wolfensberger M; Terracciano LM
    Int J Cancer; 2010 Mar; 126(5):1256-62. PubMed ID: 19697324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study.
    Lilja-Fischer JK; Kristensen MH; Lassen P; Steiniche T; Tramm T; Stougaard M; Maare C; Johansen J; Primdahl H; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
    Acta Oncol; 2023 Nov; 62(11):1384-1388. PubMed ID: 37837201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters.
    Fischer CA; Kampmann M; Zlobec I; Green E; Tornillo L; Lugli A; Wolfensberger M; Terracciano LM
    Ann Oncol; 2010 Oct; 21(10):1961-1966. PubMed ID: 20423915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma.
    Plath M; Broglie MA; Förbs D; Stoeckli SJ; Jochum W
    J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):53. PubMed ID: 30189895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors.
    Slavik M; Kazda T; Selingerová I; Šána J; Ahmad P; Gurín D; Hermanová M; Novotný T; Červená R; Dymáčková R; Burkoň P; Slabý O; Šlampa P
    Klin Onkol; 2019; 32(1):58-65. PubMed ID: 30764631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
    Haughey BH; Sinha P
    Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of keratinization with 5-year disease-specific survival in oropharyngeal squamous cell carcinoma.
    Cooper T; Biron VL; Adam B; Klimowicz AC; Puttagunta L; Seikaly H
    JAMA Otolaryngol Head Neck Surg; 2015 Mar; 141(3):250-6. PubMed ID: 25554966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing.
    Nauta IH; Rietbergen MM; van Bokhoven AAJD; Bloemena E; Lissenberg-Witte BI; Heideman DAM; Baatenburg de Jong RJ; Brakenhoff RH; Leemans CR
    Ann Oncol; 2018 May; 29(5):1273-1279. PubMed ID: 29438466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The accuracy of clinical neck staging for p16-positive and negative oropharyngeal cancer and its therapeutic implications.
    Hussain T; Thangavelu K; Kürten C; Galland L; Höing B; Deuss E; Mattheis S; Lang S; Deuschl C; Forsting M; Dörner N
    Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5339-5345. PubMed ID: 35781741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.